Acino Holding AG : Acino: Extraordinary General Meeting elects a new Board of Directors

NEWS RELEASE - PRESSEMITTEILUNG

Acino: Extraordinary General Meeting elects a new Board of Directors Aesch, December 17, 2013, 12.00 hrs - Following the successful completion of the public tender offer by Pharma Strategy Partners GmbH for Acino Holding AG, an Extraordinary General Meeting (EGM) was held today at the company's head office in Aesch to discharge the corporate bodies and to elect a new Board of Directors.

The attending shareholders represented 94.9% of Acino's share capital and consented to all agenda items. Elected to Acino's Board of Directors for a term of three years (until the Annual General Meeting 2016) were: Dr. Håkan Björklund, Toni Weitzberg, Tom Dean, Jonas Agnblad, Thomas Vetander, and Kunal Pandit. The profiles of the new Members of

the Board can be viewed at www.acino-pharma.com/BoD.

As provided for in the transaction agreement, Luzi Andreas von Bidder and Dr. Andreas Rummelt retired today from the Board of Directors after the orderly execution of the EGM. The other former Members of the Board already resigned from office with effect from the settlement of the transaction.

About Acino

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group, headquartered in Aesch BL, has 788 employees and generated revenues of EUR 143 million in the first half-year 2013.
On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, completed its public tender offer for Acino Holding AG. Pharma Strategy Partners GmbH intends to effect a full takeover of Acino, and will delist the Acino shares from the stock exchange.

Contact Calendar

Robert Schmid
Media & Investor Relations
Phone [phone] [e-mail]

6.3.2014 Annual Report 2013
6.3.2014 Media and analyst conferences
10.4.2014 General Meeting of Shareholders

Acino Holding AG

Dornacherstrasse 114

CH-4147 Aesch

Phone [phone]

Fax [phone] www.acino-pharma.com